(PDF) OA09 Preliminary Clinical Activity of Repotrectinib

OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.019

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

S. Shanna Stopatschinskaja

Publisher

Elsevier BV

Related search

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology

Respiratory Medicine

English

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

MA16.09 Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Prevalence of ROS1 Fusion in Chinese Patients With Non-Small Cell Lung Cancer

Thoracic Cancer

Respiratory Medicine

English

Repotrectinib (TPX-0005), Effectively Reduces Growth of ALK Driven Neuroblastoma Cells

Scientific Reports

Multidisciplinary

English

Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer

Oncology Letters

Cancer Research

English

P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

Journal of Thoracic Oncology

Respiratory Medicine

English